NCT06297213View on ClinicalTrials.gov

R-2487 in Patients With Sjogren's Syndrome (SS)

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

June 1, 2026

Primary Completion Date

August 30, 2028

Study Completion Date

August 30, 2028

Conditions

Sjogren's SyndromeSjögrenSjögren Syndrome, Unspecified

Interventions

DRUG

R-2487

R-2487 DP

All Listed Sponsors

lead

Rise Therapeutics LLC

INDUSTRY